|
 The London-listed company also said that under the deal, which is
expected to close in the fourth quarter of 2021, Covis will also
cover certain ongoing development costs related to the medicines.
AstraZeneca, which has several new medicines in its pharmaceutical
pipeline, including COVID-19 drugs and a vaccine, expects the
agreement to help sharpen its focus on priority medicines in its
respiratory and immunology portfolio.
Covis had previously acquired the rights to other respiratory
medicines Alvesco, Omnaris and Zetonna from AstraZeneca in 2018.
[to top of second column] |
 Eklira and Duaklir, used to
treat chronic obstructive pulmonary disease (COPD)
or smokers' lung, had generated revenues of $143
million for AstraZeneca in geographies covered
by a previous deal when the drugmaker had bought
those rights.
(Reporting by Muhammed Husain in Bengaluru;
Editing by Shounak Dasgupta and Uttaresh.V)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
